Income taxes	3 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income taxes	Income taxesIn determining quarterly provisions for income taxes, the Company uses the annual estimated effective tax rate applied to the actual year-to-date profit or loss, adjusted for discrete items arising in that quarter. The Company’s annual estimated effective tax rate differs from the U.S. federal statutory rate primarily as a result of state taxes, foreign taxes, and changes in the Company’s valuation allowance against its deferred tax assets. For the three months ended December 31, 2022, the Company recorded an immaterial provision for income taxes. For the three months ended December 31, 2021, the Company recorded $10.5 million income tax benefit, mainly due to the deferred tax liability assumed as part of the acquisition of AbX Biologics, Inc.